Tranilast
Code | Size | Price |
---|
TAR-T2690-5mg | 5mg | £101.00 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here. |
Quantity:
TAR-T2690-1mL | 1 mL * 10 mM (in DMSO) | £111.00 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here. |
Quantity:
TAR-T2690-10mg | 10mg | £111.00 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here. |
Quantity:
TAR-T2690-25mg | 25mg | £119.00 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here. |
Quantity:
TAR-T2690-100mg | 100mg | £168.00 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here. |
Quantity:
TAR-T2690-200mg | 200mg | £225.00 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here. |
Quantity:
Prices exclude any Taxes / VAT
Overview
Regulatory Status: RUO
Shipping:
cool pack
Storage:
-20℃
Images
Documents
Further Information
Bioactivity:
Tranilast, an antiallergic drug, suppresses lipid mediator and cytokine release from inflammatory cells, therefore utilized in the treatment of allergic disorders.
CAS:
53902-12-8
Formula:
C18H17NO5
Molecular Weight:
327.33
Pathway:
GPCR/G Protein; Immunology/Inflammation; Endocrinology/Hormones
Purity:
0.9957
SMILES:
COc1c(OC)cc(C=CC(Nc2c(C(O)=O)cccc2)=O)cc1
Target:
RAAS; Prostaglandin Receptor
References
1. Suzawa H, et al. Jpn J Pharmacol, 1992, 60(2), 91-96.
2. Suzawa H, et al. Jpn J Pharmacol, 1992, 60(2), 85-90.
3. Miyazawa K, et al. Atherosclerosis, 1995, 118(2), 213-221.
4. Martin J, et al. Cardiovasc Res, 2005, 65(3), 694-701.
5. Shiota N, et al. Circulation, 1999, 99(8), 1084-1090.
6. Huang R, Li S, Tian C, et al. Thermal stress involved in TRPV2 promotes tumorigenesis through the pathway of PI3K/Akt/mTOR in esophageal squamous cell carcinoma[J]. 2020
7. Huang R, Wang F, Yang Y, et al. Recurrent activations of transient receptor potential vanilloid?1 and vanilloid?4 promote cellular proliferation and migration in esophageal squamous cell carcinoma cells[J]. FEBS open bio. 2019 Jan 18;9(2):206-225.
8. Liu J, Zhao Z, Wen J, et al. TNF-? differently regulates TRPV2 and TRPV4 channels in human dental pulp cells[J]. International endodontic journal. 2019.
9. Weiqiang H, Longshan Z, Mi Y, et al. Cancer-Associated Fibroblasts Promote the Survival of Irradiated Nasopharyngeal Carcinoma Cells via the NF-?B Pathway[J]. Journal of Experimental & Clinical Cancer Research. 2020